Myocardial Revascularization Surgery Hits a Plateau

Hopes were raised high by the ARTS study, when set to show the benefit of bilateral internal mammary arteries (BIMA) during coronary artery bypass graft surgery compared over the use of a single internal mammary artery (SIMA) at 10 year follow up, but only one sub-study was able to show an advantage over radial grafts.

La meseta por la que transcurre la cirugía desde hace varios añosSimilarly, hopes were raised high by the long-term benefits of off-pump versus on-pump coronary artery bypass grafting (CABG), with a list of potential benefits that got longer and longer by the minute that has only led to disappointment. Nothing has changed in the CABG scene for years, and though it is still an excellent revascularization strategy for many patients, it has reached a plateau and there are no further studies to broaden our horizon.

 

And even though cutting-edge stents come out day after day, these also appear to be reaching a plateau. All new devices, despite their many theoretical advantages, have at best been shown non-inferior when compared against the gold standard (the everolimus eluting stent), let alone compared against bioresorbable scaffolds.


Read also: Practical Management of Coronary Perforations.


The present study compared long term survival and morbidity after on pump and off pump CABG.

 

Mandatory clinical and administrative registries were linked to identify patients who underwent CABG between 2005 and 2011, by surgeons who had performed at least 100 off-pump or on-pump CABG operations (to meet expert operator criterion). Survival, stroke, myocardial infarction, repeat revascularization, and new dialysis requirement were analyzed using propensity score and other methods. Median follow-up was 6.8 years.

 

During this period, out of 42570 patients undergoing CABG, 6950 off pump and 15295 on pump patients met inclusion criteria.


Read also: How to predict post TAVR quality of life in “real world” patients.


Off pump CABG was associated to higher mortality (33.4% vs. 29.6% at 10 years; HR: 1.11; CI 95%: 1.04 to 1.18; p=0.002) compared against on pump. In addition, off pump CABG was associated to more chances of incomplete revascularization (15.7% vs. 8.8%; p<0.001), which resulted a mortality predictor at long term (HR: 1.10; CI 95% CI: 1.03 to 1.17; p=0.006) and new revascularization rate also resulted higher (15.4% vs. 14.0% at 10 years; HR: 1.17; CI 95%: 1.01 to 1.37; p=0.048).

 

There were no differences in stroke, acute myocardial infarction or new dialysis.

 

Conclusion

Off pump CABG was associated to higher incomplete revascularization, higher new revascularization rate and higher mortality at 10 years, compared against on pump CABG. These data suggest on pump CABG might be the appropriate choice for most patients undergoing myocardial revascularization surgery.

 

Original title: Long-Term Outcomes After Off-Pump Versus On-Pump Coronary Artery Bypass Grafting by Experienced Surgeons.

Reference: Joanna Chikwe et al. J Am Coll Cardiol 2018;72:1478–86.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Esta es una entrada en ingles

demo en ingles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...